Alternative lengthening of telomeres does exist in various canine sarcomas

Molecular Carcinogenesis

Volumn 56, Issue 3, 2017, Pages 923-935

  Kreilmeier, Theresa ^a,b   Sampl, Sandra ^b   Deloria, Abigail J ^b   Walter, Ingrid ^a   Reifinger, Martin ^a   Hauck, Marlene ^c   Borst, Luke B ^c   Holzmann, Klaus ^b   Kleiter, Miriam ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

cancer; comparative; dog; non determined TMM; telomerase independent; telomere length

Indexed keywords

DAXX PROTEIN; DNA; PROTEIN P53; TELOMERASE; ATRX PROTEIN, HUMAN; DNA HELICASE; NUCLEAR PROTEIN; TP53 PROTEIN, HUMAN; TRANSCRIPTIONAL REGULATOR ATRX;

ANGIOSARCOMA; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; GENE EXPRESSION; HISTIOCYTIC SARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSTEOSARCOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULSED FIELD GEL ELECTROPHORESIS; QUANTITATIVE ANALYSIS; RESTRICTION FRAGMENT; SARCOMA; TELOMERE HOMEOSTASIS; TELOMERE LENGTH; ANIMAL; DOG DISEASE; GENE EXPRESSION REGULATION; GENETICS; NEUROBLASTOMA; PATHOLOGY; TELOMERE; TUMOR CELL LINE; VETERINARY;

ANIMALS; CELL LINE, TUMOR; DNA HELICASES; DOG DISEASES; DOGS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; SARCOMA; TELOMERE; TELOMERE HOMEOSTASIS; TUMOR SUPPRESSOR PROTEIN P53; X-LINKED NUCLEAR PROTEIN;

EID: 85012923685     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22546     Document Type: Article

References (57)

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345:458–460.
2. Nasir L, Devlin P, McKevitt T, Rutteman G, Argyle DJ. Telomere lengths and telomerase activity in dog tissues: A potential model system to study human telomere and telomerase biology. Neoplasia 2001; 3:351–359.
3. Nasir L. Telomeres and telomerase: Biological and clinical importance in dogs. Vet J 2008; 175:155–163.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.
5. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33:787–791.
6. Kow K, Thamm DH, Terry J, et al. Impact of telomerase status on canine osteosarcoma patients. J Vet Intern Med 2008; 22:1366–1372.
7. Funakoshi Y, Nakayama H, Uetsuka K, Nishimura R, Sasaki N, Doi K. Cellular proliferative and telomerase activity in canine mammary gland tumors. Vet Pathol 2000; 37:177–183.
8. Yazawa M, Okuda M, Setoguchi A, et al. Measurement of telomerase activity in dog tumors. J Vet Med Sci 1999; 61:1125–1129.
9. Argyle DJ, Nasir L. Telomerase: A potential diagnostic and therapeutic tool in canine oncology. Vet Pathol 2003; 40:1–7.
10. Nasir L, Gault E, Campbell S, et al. Isolation and expression of the reverse transcriptase component of the Canis familiaris telomerase ribonucleoprotein (dogTERT). Gene 2004; 336:105–113.
11. Gocha AR, Harris J, Groden J. Alternative mechanisms of telomere lengthening: Permissive mutations, DNA repair proteins and tumorigenic progression. Mutat Res 2013; 743–744:142–150.
12. Durant ST. Telomerase-independent paths to immortality in predictable cancer subtypes. J Cancer 2012; 3:67–82.
13. Lovejoy CA, Li W, Reisenweber S, et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet 2012; 8:e1002772.
14. O'Sullivan RJ, Arnoult N, Lackner DH, et al. Rapid induction of alternative lengthening of telomeres by depletion of the histone chaperone ASF1. Nat Struct Mol Biol 2014; 21:167–174.
15. Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science 2015; 347:273–277.
16. Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010; 584:3800–3811.
17. Lau LM, Dagg RA, Henson JD, Au AY, Royds JA, Reddel RR. Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Res 2013; 41:e34.
18. Henson JD, Cao Y, Huschtscha LI, et al. DNA C-circles are specific and quantifiable markers of alternative-lengthening-of-telomeres activity. Nat Biotechnol 2009; 27:1181–1185.
19. Cesare AJ, Reddel RR. Telomere uncapping and alternative lengthening of telomeres. Mech Ageing Dev 2008; 129:99–108.
20. Heaphy CM, Subhawong AP, Hong SM, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 2011; 179:1608–1615.
21. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012; 482:226–231.
22. Chen YJ, Hakin-Smith V, Teo M, et al. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res 2006; 66:6473–6476.
23. Fenger JM, London CA, Kisseberth WC. Canine osteosarcoma: A naturally occurring disease to inform pediatric oncology. ILAR J 2014; 55:69–85.
24. Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res 2012; 2:14.
25. Kotilingam D, Lev DC, Lazar AJ, Pollock RE. Staging soft tissue sarcoma: Evolution and change. CA Cancer J Clin 2006; 56:282–291. quiz 314–285.
26. Jane MJ, Hughes PJ. Disease incidence and results of extremity lesion treatment: Mersey region soft tissue sarcomas (1975–1985). Sarcoma 1998; 2:89–96.
27. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002; 43:240–246.
28. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968; 40:307–318.
29. Schweiger N, Hauck M, Steinhoff H, et al. Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling. Mol Carcinog 2015; 54:841–852.
30. Zavodovskaya R, Liao AT, Jones CL, et al. Evaluation of dysregulation of the receptor tyrosine kinases Kit, Flt3, and Met in histiocytic sarcomas of dogs. Am J Vet Res 2006; 67:633–641.
31. Scheel C, Schaefer KL, Jauch A, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001; 20:3835–3844.
32. Pikor LA, Enfield KS, Cameron H, Lam WL. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp 2011; 49:e2763.
33. Sampl S, Pramhas S, Stern C, Preusser M, Marosi C, Holzmann K. Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade. Transl Oncol 2012; 5:56–65.
34. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques 2008; 44:807–809.
35. Colitz CM, Barden CA, Lu P, Chandler HL. Expression and characterization of the catalytic subunit of telomerase in normal and cataractous canine lens epithelial cells. Mol Vis 2006; 12:1067–1076.
36. Kreilmeier T, Mejri D, Hauck M, Kleiter M, Holzmann K. Telomere transcripts target telomerase in human cancer cells. Genes 2016; 7:E46.
37. Zielke S, Bodnar A. Telomeres and telomerase activity in scleractinian corals and Symbiodinium spp. Biol Bull 2010; 218:113–121.
38. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005; 11:217–225.
39. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011; 333:425.
40. Bower K, Napier CE, Cole SL, et al. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres. PLoS ONE 2012; 7:e50062.
41. Poon SS, Lansdorp PM. Quantitative fluorescence in situ hybridization (Q-FISH). Curr Protoc Cell Biol 2001; Chapter 18:Unit 18:14.
42. Khelifi AF, D'Alcontres MS, Salomoni P. Daxx is required for stress-induced cell death and JNK activation. Cell Death Differ 2005; 12:724–733.
43. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008; 37:454–460.
44. Loukopoulos P, Thornton JR, Robinson WF. Clinical and pathologic relevance of p53 index in canine osseous tumors. Vet Pathol 2003; 40:237–248.
45. Liau JY, Tsai JH, Yang CY, et al. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas. Human Pathol 2015; 46:1360–1366.
46. Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M. Alternative lengthening of telomeres as a prognostic factor in malignant fibrous histiocytomas of bone. Anticancer Res 2010; 30:4959–4962.
47. Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: A comparative analysis. BMC Cancer 2010; 10:254.
48. Costa A, Daidone MG, Daprai L, et al. Telomere maintenance mechanisms in liposarcomas: Association with histologic subtypes and disease progression. Cancer Res 2006; 66:8918–8924.
49. Decker B, Davis BW, Rimbault M, et al. Comparison against 186 canid whole genome sequences reveals survival strategies of an ancient clonally transmissible canine tumor. Genome Res 2015; 25:1646–1655.
50. Lee YK, Park NH, Lee H. Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma. Int J Gynecol Cancer 2012; 22:434–441.
51. Cunningham JM, Johnson RA, Litzelman K, et al. Telomere length varies by DNA extraction method: Implications for epidemiologic research. Cancer Epidemiol Biomarkers Prev 2013; 22:2047–2054.
52. Zhong S, Salomoni P, Ronchetti S, Guo A, Ruggero D, Pandolfi PP. Promyelocytic leukemia protein (PML) and Daxx participate in a novel nuclear pathway for apoptosis. J Exp Med 2000; 191:631–640.
53. Napier CE, Huschtscha LI, Harvey A, et al. ATRX represses alternative lengthening of telomeres. Oncotarget 2015; 6:16543–16558.
54. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7:2984–2997.
55. Pietrantonio F, Biondani P, Perrone F, et al. TP53 mutations in advanced colorectal cancer: The dark side of the moon. Oncology 2014; 86:289–294.
56. Gocha AR, Nuovo G, Iwenofu OH, Groden J. Human sarcomas are mosaic for telomerase-dependent and telomerase-independent telomere maintenance mechanisms: Implications for telomere-based therapies. Am J Pathol 2013; 182:41–48.
57. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001; 21:3862–3875.